Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02149225 : GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
PhasePhase 1
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

1. Histologically confirmed, newly diagnosed GB (astrocytoma WHO grade IV)

2. HLA phenotype defined by warehouse composition (HLA-A*02:01 or HLA-A*24:02 positive
patients only; both as determined by a PCR-based 4-digit typing method)

3. Gross total resection (as defined by less than 1 cm2 residual tumor mass on the
largest perpendicular axes in post-operative scan taken within 48 h post-surgery;
standard MRI conformable to the present national and international guidelines is
sufficient)

4. At least 0.5 g tumor tissue freshly cryopreserved during surgery

5. Age ?18 years

6. KPS ?70%

7. Life expectancy > 6 months

8. Patient is a candidate for and willing to receive standard CRT with TMZ followed by
maintenance TMZ cycles

9. Patient is not on steroids or on stable or decreasing steroid levels not exceeding 2
mg/day dexamethasone (or equivalent doses of other steroids) during the last 3 days
prior to enrollment

10. Absolute lymphocyte count (ALC) >1.0 x109/L (re-screening of lymphocyte counts is
allowed)

11. Ability of subject to understand and the willingness to sign written informed consent
for study participation. Written consent by a legally authorized representative is
not sufficient.

12. Availability of an APVAC analysis and manufacturing slot confirmed by the sponsor

13. Female patients who are post-menopausal (no menstrual period for a minimum of 1
year), or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
hysterectomy), practice one of the following medically acceptable methods of birth
control (hormonal methods, intrauterine device or double-barrier methods) or practice
total abstinence

14. Male patients willing to use contraception (condoms with spermicidal jellies or
cream) upon study entry and during the course of the study, have undergone vasectomy
or are practicing total abstinence

Exclusion Criteria:

1. Abnormal (? Grade 2 CTCAE v4.0) laboratory values for hematology, liver and renal
function (serum creatinine). In detail the following values apply as exclusion
criteria:

1. Hemoglobin < 10 g/dL (6.2 mmol/L)

2. White blood cell count (WBC) decrease (<3.0 x109/L) or increase (>10.0 x109/L)

3. Absolute neutrophil count (ANC) decrease < 1.5 x109/L

4. Platelet count decrease < 75 x109/L

5. Bilirubin > 1.5 x ULN (upper limit of normal according to the performing lab's
reference range)

6. ALAT > 3 x ULN

7. ASAT > 3 x ULN

8. GGT6 > 2.5 x ULN

9. Serum creatinine increased > 1.5 x ULN

2. HIV infection or active Hepatitis B or C infection, or active infections requiring
oral or intravenous antibiotics or that can cause a severe disease and pose a severe
danger to lab personnel working on patients' blood or tissue (e.g. rabies).

3. Prior therapy for glioma (except surgery and steroids) including but not limited to
carmustine wafers and immunotherapy

4. Any condition contraindicating leukapheresis from peripheral veins

5. Concurrent participation in another interventional clinical trial studying a drug or
treatment regimen.

6. Clinically relevant autoimmune diseases (with the exception of thyroid diseases)

7. Immunosuppression, not related to prior treatment for malignancy, or prior drug
reaction

8. Any condition that in the judgment of the investigator interferes with the
probability that an individual patient may receive and benefit from APVAC
vaccinations (e.g. high risk of early disease progression / recurrence;
immunocompromised status; anticipated compliance problems)

9. Serious illness or condition, which according to the investigator, poses an undue
risk for the patient when participating in the trial, including, but not limited to,
any of the following:

- Clinically significant cardiovascular disease

- New York Heart Association class III-IV congestive heart failure

- Symptomatic peripheral vascular disease

- Severe pulmonary dysfunction

- Severe diabetes

- Severe mental retardation

10. History of other malignancies (except for adequately treated basal or squamous cell
carcinoma or carcinoma in situ) within the last 5 years unless the patient has been
disease-free for 5 years

11. Pregnancy or breastfeeding
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02149225      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740